Dual Anti-Mesothelin CAR T-Cell Therapy/PD-L1 Checkpoint Inhibitor (Atara)

N/A

Report date: 2025/01/26 18:09:20

Base Information

Drug NameDual Anti-Mesothelin CAR T-Cell Therapy/PD-L1 Checkpoint Inhibitor (Atara)
Drug Alias Namedual anti-mesothelin CAR T-cell therapy/PD-L1 checkpoint inhibitor (Memorial Sloan Kettering Cancer Center)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMesothelin modulatorsProgrammed death-ligand 1 blockers
TargetsMesothelinProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumoursMesothelioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesAtara Biotherapeutics Inc
Inactive CompaniesMemorial Sloan Kettering Cancer Center
Active IndicationsSolid tumoursMesothelioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A